1. Mylonakis E, Ausubel FM, Perfect JR, Heitman J, Calderwood SB. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci USA 2002; 99:15675-80.

  2. Mylonakis E, Idnurm A, Moreno R, El Khoury J, Rottman JB, Ausubel FM, Heitman J, Calderwood SB. Cryptococcus neoformans Kin1 protein kinase homolog, identified through a C. elegans screen, promotes virulence in mammals. Mol Microbiol 2004; 54:407-19.

  3. Apidianakis Y, Rahme LG,  Heitman J, Ausubel FM, Calderwood SB, Mylonakis E. Challenge of Drosophila melanogaster with Cryptococcus neoformans and the role of the fly Innate immune response. Eukaryot Cell 2004; 3:413-9.

  4. Mylonakis E, Moreno R, El Khoury J, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 2005; 73: 3842-50.

  5. Mylonakis E, Aballay A. Worms and flies as genetically tractable animal models to study host-pathogen interactions. Infect Immun 2005;73:3833-41.

  6. Tang RJ, Breger J, Idnurm A, Gerik K, Lodge JK, Heitman J, Calderwood SB, Mylonakis E. Cryptococcus neoformans gene involved in mammalian pathogenesis identified by a C. elegans progeny-based approach. Infect Immun 2005; 73: 8219-25. http://iai.asm.org/cgi/reprint/73/12/8219

  7. Aperis G, Mylonakis E. New triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs. 2006;15:579-602.

  8. Kwon DS, Mylonakis E. Posaconazole: A new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007;8:1167-78.

  9. Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog. 2007;3:e101. http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.0030101

  10. Mylonakis E, Pukkila-Worley R. Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother. 2008;9:551-60.

  11. Maadani A., Fox KA, Mylonakis E, Garsin DA. Enterococcus faecalis mutations affecting virulence in the C. elegans model host. Infect Immun. 2007;75:2634-7.

  12. Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB, Mylonakis E. Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain. Microbes Infect. 2007; 9:729-34.

  13. Fuchs BB, Tang RJ, Mylonakis E. The temperature-sensitive role of Cryptococcus neoformans ROM2 in cell morphogenesis. PLoS ONE. 2007;2:e368.

    http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000368

  14. Breger J, Fuchs BB, Aperis G, Moy T, Ausubel FM, Mylonakis E. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog. 2007;3:e18.

  15. Fuchs BB, Tegos GP, Hamblin MR, Mylonakis E. Susceptibility of Cryptococcus neoformans to photodynamic inactivation is associated with cell wall integrity. Antimicrob Agents Chemother. 2007;51:2929-36. http://aac.asm.org/cgi/reprint/51/8/2929

  16. Thakur JK, Arthanari H, Yang F, Pan S-J, Fan X, Breger J, Frueh DP, Gulshan K, Li D, Mylonakis E, Struhl K, Moye-Rowley WS, Cormack BP, Wagner G, Näär AM. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008; 452:604-9.

  17. Mylonakis E. Who killed the worm and other fungal pathogenesis insights. Microbe 2007;2:600-6.http://www.asm.org/microbe/index.asp?bid=55040

  18. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr., Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus. J Infect Dis 2009;199(4):532-6.

  19. Tampakakis E, Okoli I, Mylonakis E. A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nature Protocols. (in press).

  20. Peleg A, Tampakakis E, Fuchs BB, Eliopoulos G, Moellering RC Jr, Mylonakis E Prokaryote-eukaryote interactions identified using Caenorhabditis elegans. Proc Natl Acad Sci USA. 2008;105:14585-90. http://www.pnas.org/content/105/38/14585

  21. Cowen LE,  Singh SD, Köhler JR, Collins C, Zaas AK, Schell W, Aziz H, Mylonakis E, Perfect JR, Whitesel L, Lindquist S. Harnessing Hsp90 function as a novel therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009;106:2818-23.

  22. Means TK, Mylonakis E, Tampakakis E, Puckett L, Stewart CR, Pukkila-Worley R, Hickman SE, Moore KJ, Calderwood SB, Hacohen N, Luster AD, El-Khoury J. Evolutionary-conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med 2009;206(3):637-53.

  23. Ziakas P, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94(7):998-1005.

  24. Tampakakis E, Peleg A, Mylonakis E. The interaction of Candida albicans with an intestinal pathogen; Salmonella enterica serovar Typhimurium. Eukaryot Cell 2009;8:732-7.

  25. Peleg A, Jara S, Monga D, Eliopoulos G, Moellering RC Jr, Mylonakis E. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics Antimicrob Agents Chemother 2009;53:2605-9.

  26. Ziakas P, Mylonakis E. 4-months of rifampin compared to 9-months of isoniazid for the management of latent tuberculosis: A meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009;49(10):1557-64.

  27. Ngamskulrungroj P, Himmelreich U, Breger J, Wilson C, Chayakulkeeree M, Krockenberger MB, Malik R, Daniel HM, Toffaletti D, Djordjevic JT, Mylonakis E, Meyer W, Perfect JR. The trehalose synthesis pathway: an integral part for the virulence composite for Cryptococcus gattii. Infect Immun 2009;77(10):4584-96.

  28. Okoli I, Coleman J, Tempakakis E, An F, Holson E, Wagner F, Conery AL, Larkins-Ford J, Wu G, Stern A, Ausubel FM, Mylonakis E. Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS ONE 2009;4:e7025.

  29. Pukkila-Worley R, Peleg AY, Tampakakis E, Mylonakis E. Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model Eukaryot Cell 2009;8(11):1750-8.

  30. Dai T, Tegos G, Zhiyentayev T, Mylonakis E, Hamblin MR. Photodynamic therapy for methicillin-resistant Staphylococcus aureus infection in a mouse skin abrasion model. Laser Surg Med 2010;42: 38-44

  31. Coleman J, Okoli I, Tegos GT, Holson EB, Wagner FF, Hamblin MR, Mylonakis E. Characterization of plant-derived saponin natural products against Candida albicans. ACS Chem Biol 2010;5:321-32.

  32. Fuchs BB, Eby J, Nobile CJ, El Khoury JB, Mitchell AP, Mylonakis E. Role of filamentation in Galleria mellonella killing by Candida albicans. Microbes Infect. 2010;12(6):488-96.

  33. Carneiro H, Coleman J, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: A case series and literature review. Medicine [Baltimore]. (in press).
    Manolakaki D, Velmahos G, Kourkoumpetis T, Chang Y, Alam HB, De Moya MM, Mylonakis E. Candida infection and colonization among trauma patients Virulence. (in press).

  34. Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E, Manolakaki D, Coleman JJ, Mylonakis E. The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients. Mycopathologia. 2010 (in press)

  35. Kourkoumpetis T, Manolakaki D, Velmahos G, Chang Y, Alam HB, De Moya MM, Sailhamer EA, Mylonakis E. Candida infection and colonization among non-trauma emergency surgery patients. Virulence. (in press).

  36. Fuchs BB, Bishop LR, Kovacs JA, Mylonakis E. Galleria mellonella are resistant to Pneumocystis murina infection. Mycopathologia. (in press).

Home Publications MGH Infectious Diseases Division
©2010 Mass General Hospital. All Rights Reserved.
MGH Homepage Home